314 - Real-World Outcomes Using a Shear-Thinning Conformable Hydrogel for Peripheral Embolization: A Single-Center Experience

Purpose: Evaluate technical/clinical outcomes and safety of a conformable, shear-thinning hydrogel embolic across hemorrhagic and non-hemorrhagic peripheral indications.

Materials and Methods: Single-center retrospective review of consecutive arterial embolizations performed with the hydrogel from January 2022 to July 2025. Outcomes included technical success, clinical success, complications (SIR-graded), and 30-day re-intervention. Use of adjunctive embolics and indication class (hemorrhagic vs non-hemorrhagic) were compared.

Results: 150 procedures were analyzed. Technical success was 100% (150/150). Overall clinical success was 87.3% (131/150). Indications were predominantly hemorrhage (122/150, 81.3%) while non-hemorrhagic comprised 28/150 (18.7%). Clinical success was higher for non-hemorrhagic vs hemorrhagic cases (100% vs 84.4%; p=0.0247). Thirty-day re-intervention occurred in 6.0% (9/150). Complications occurred in 8.7% (13/150); major complications (SIR Grade ≥3) in 6.7% (10/150); no procedure-related deaths. Non-target embolization was uncommon (0.7%). In paired labs (n=124), hemoglobin increased post-procedure (meanΔ +0.59 g/dL; p=0.0016), consistent with hemostasis. Adjunctive embolics were used in 48.7% (73/150) of cases although outcomes did not differ vs hydrogel alone for clinical success (89.0% vs 85.7%; p=0.627) or complications (8.2% vs 11.7%; p=0.590).

Conclusion: The shear-thinning conformable hydrogel achieved uniform technical success, favorable clinical effectiveness, and acceptable safety across diverse peripheral embolization scenarios. Efficacy was robust for hemorrhage and non-hemorrhage, with low re-intervention and complication rates and no apparent dependence on adjunctive embolics.